Get More Information on mRNA Therapeutics Market - Request Sample Report
The mRNA Therapeutics Market Size was valued at USD 11.82 billion in 2023 and is expected to grow to USD 48.65 billion by 2032 and grow at a CAGR of 17.04 % over the forecast period of 2024-2032.
The mRNA therapeutics market gained much attention due to the nature of the field in discussing chronic diseases and the advantages of DNA vaccines. Higher production efficiency and distribution capabilities along with safety profiles have enhanced the acceptance and popularity of mRNA vaccines. The U.S. provided reliable clinical results and used authorization urgently, late. FDA Approvals for COVID-19 mRNA vaccines, which showed a high efficacy of 94.1% in preventing symptomatic cases. The expansion of clinical trials across the globe and the growing use of stem cell therapy also drive the industry in line with market growth.
Biopharmaceuticals, monoclonal antibodies, peptides, and nucleic acids are becoming promising therapeutic approaches, and there has been an influx of new and innovative therapies for treating diseases, which has placed a strong focus on mRNA technologies both for the treatment and prevention of such diseases. Over the last decade, several technological breakthroughs have solved earlier challenges of mRNA therapy: mRNA has a short half-life and intrinsic immunogenicity. Several technologies, that helped in its adoption, included easier production, reduced cytotoxicity, and clinical validation.
The market of mRNA therapeutics is growing fast with high levels of innovation and technological advancement. Notably, the focus will now shift to oncology and rare disease applications. Some of the important technology trends include improvements in lipid nanoparticle delivery systems, personalized mRNA sequences, and self-amplifying platforms. It can also be noted that significant partnerships and collaborations across the industry are a market characteristic to enhance product portfolios and expand their market reach. For example, the strategic collaboration of BioNTech SE with CEPI in September 2023 to develop an mRNA-based Mpox vaccine fits this bill.
Regulatory trends are also friendly to innovation. With flexible approval processes now being adopted by agencies like the FDA, having made provision for expedited authorization as was seen in the case of the Pfizer-BioNTech COVID-19 vaccine, a new way of planning the timeline for approval might be noticed in the future. Companies are also building up their mRNA product lines. Moderna, Inc., and organizations from Australia launched an mRNA platform in November 2023 for faster therapeutic development. Complementing this is Sanofi opening a new mRNA research facility at Griffith University for faster R&D. It indicates growth in the healthy market for mRNA therapeutics while the R&D activities are picking up alongside increasing technological improvements and acceptance of these novel treatments.
Drivers
Catalysts Fueling Growth in the mRNA Therapeutics Market are Innovations, Investments, and Expanded Applications
mRNA vaccine for COVID-19 has shown spectacular success. Such a success has dramatically increased the interest and investment in the underlying technology. The success is demonstrating the potential of mRNA-based treatments for diseases of various genres, be it infectious or rare chronic conditions. Advances in mRNA technology, especially the improvement in lipid nanoparticle delivery systems and self-amplifying platforms, further enhance the feasibility and efficacy of mRNA therapeutics. The main driver in the market for mRNA products is increased governmental and institutional funding as well as strategic partnerships and collaborations with big pharmaceutical companies. An increasing prevalence of chronic diseases and thus a progressive demand for personalized medicine further boost the market. Enhanced clinical research along with an expansion of mRNA application beyond COVID into areas like oncology and rare diseases fuel the growth in the market. The sector, as demonstrated in the case of Moderna's extension into new therapeutic areas and CureVac's Phase 2 study of modified mRNA vaccines, is one of the continuing innovations and possibility of future revenue growth.
Restraint
High Development and Production Costs
Short Half-Life and Immunogenicity Issues
Public Skepticism and Acceptance
Complex Manufacturing Processes
By Application
Application is the basis for the division of the market into mRNA therapeutics for rare genetic diseases, oncology, respiratory diseases, infectious diseases, and other categories. Infectious diseases were the highest-end application in the market in 2023 due primarily to the rise in the demand for COVID-19 treatments. mRNA vaccines are increasingly being adopted and more candidates in clinical trials for different infectious diseases are expected to continue fueling growth in this segment. For example, this August 2021, the Pfizer-BioNTech COVID-19 mRNA vaccine received an Emergency Use Authorization or EUA among individuals of 16 years and above. In September 2023, BioNTech and Pfizer reportedly secured U.S. FDA approval for its mRNA-based COVID-19 vaccine, COMIRNATY 2023-2024, for use in adults 12 years of age and older. The next wave of FDA approvals for innovative mRNA medicines should further speed up this class.
The oncology segment is expected to grow at the highest compound annual growth rate (CAGR) during the forecast period. mRNA technology has exhibited immense potential in cancer research, with numerous clinical trials currently ongoing in RNA vaccines and therapies for various types of cancers. For instance, personalized mRNA cancer vaccines can provoke an exact immune response to devastate the cancer cells-one promising development in the treatment of cancer.
By Type
The mRNA therapeutics market can be further divided into two types: prophylactic and therapeutic. In 2023, the prophylactic segment accounted dominated market share. This is primarily due to the high revenue generated through COVID-19 vaccines. With the introduction of vaccines across other diseases such as influenza and RSV, the segment is expected to rise going forward. Many top companies are carrying out clinical studies and developing RNA vaccines for COVID-19, flu, HIV, and more against viral diseases to gain market share and take in revenue-positive business deals. In February 2023, RVAC Medicines initiated a phase IB clinical trial in Singapore of three candidates for its COVID-19 mRNA vaccine with approval from the Health Sciences Authority (HSA).
On the other hand, the therapeutic segment is expected to achieve the highest compound annual growth rate between 2024 and 2032. This growth is due to the huge investment made by the primary market players in the development of novel and more effective RNA therapeutics. For instance, during July 2022, Axcelead, Inc. subsidiarities, Axcelead Drug Discovery Partners, Inc., and ARCALIS, Inc., collaboratively provided comprehensive drug discovery support services mainly for mRNA-based vaccines and therapeutics. With the investment, the therapeutic segment is likely to increase in future years.
By End-Use
The mRNA therapeutics market is segmented by end-use into hospitals & clinics, research organizations, and other categories. Hospitals & clinics accounted for the largest share of 45.3% in 2023. This segment is also expected to grow at the fastest rate from 2024 to 2032. The prime reason is the growing demand for mRNA-based vaccines and therapeutics for controlling chronic diseases with concurrent growth in patients being treated in such facilities.
The "other" category, including specialty pharmacies, is also anticipated to grow by considerable percentage points over the forecasting period. Specialty pharmacies are integral to the distribution and delivery of mRNA vaccines, and this is further facilitated by the specific storage requirements inherent in mRNA vaccines. For example, the Pfizer-BioNTech mRNA COVID-19 vaccine, which initially required ultra-low-temperature storage, has benefited greatly from these pharmacies' specialized handling expertise. The growth in specialty pharmacies mirrors this essential role in the management of temperature-sensitive medications.
Regional Insights
North America dominated the mRNA therapeutics market in 2023 with a humongous revenue share of 40.3%. This is because of heavy research funding, federal programs for RNA-based medicines, and a large number of clinical trials. For example, this 'vaccine development in a matter of few months' is possible only due to the significant research support given by the NIH and other federal bodies. The US market will continue to be promising and is set to grow further with appropriate strategy steps by leading players who join other organizations or businesses.
Europe is a very attractive market, especially because of excellent government support, state-of-the-art research infrastructure, and successful Covid-19 mRNA vaccines. The UK will continue growing since government deals related to pandemic management will continue in the future. France is becoming increasingly investing in research for mRNA vaccines. Germany would be growing on its own because it has immense numbers of mRNA providers and is expanding.
The fastest growth from 2024 to 2032 is expected in the Asia Pacific region due to the rising investment in biotech, better healthcare infrastructure, and focus on precision medicine. Developments that led to the growth of trends include those in China, wherein there is ample investment into mRNA research, and Japan, where efforts are seen in personalized medicine.
The Middle East and Africa are poised to grow with improved investments in health care coupled with increased interest in advanced medical solutions. Biotechnology is driven by the commitment in the region by the UAE, as well as by the growth of the biologics industry in Saudi Arabia. Multinational and regional pharmaceutical players continue to grow the market in Kuwait.
Need any customization research on mRNA Therapeutics Market - Enquiry Now
Moderna Inc.
CureVac N.V.
Sanofi
GSK Plc.
Argos Therapeutics Inc.
Ethris
Pfizer Inc.
AstraZeneca
Translate Bio, Inc
Sangamo therapeutics
Etherna Immunotherapies.
Crisper Therapeutics and others
In September 2023, Moderna, Inc. broadened its mRNA research to encompass oncology, respiratory diseases, and rare conditions. This strategic expansion was expected to boost the company’s revenue.
In August 2023, CureVac began dosing the first participant in a Phase 2 study of modified COVID-19 mRNA vaccine candidates, developed in collaboration with GSK Plc.
| Report Attributes | Details |
| Market Size in 2023 | US$ 11.82 Billion |
| Market Size by 2032 | US$ 48.65 Billion |
| CAGR | CAGR of 17.04% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Application (Rare genetic disease, Respiratory disease, Infectious disease) • By type (Prophylactic vaccines, Therapeutic Vaccines, Therapeutic Drugs) • By end user (Hospitals and clinics, Research Organizations) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Moderna Inc., BioNTech SE, CureVac N.V., Arcturus Therapeutics, Sanofi, GSK Plc., Argos Therapeutics Inc., Ethris, Pfizer Inc. and Others |
| Key Drivers | • Catalysts Fueling Growth in the mRNA Therapeutics Market are Innovations, Investments, and Expanded Applications |
| Market Restraints | • High Development and Production Costs • Short Half-Life and Immunogenicity Issues |
Ans: The mRNA Therapeutics Market size was valued at US$ 11.82 Bn in 2023.
Ans: The mRNA Therapeutics Market is growing at a CAGR of 17.04% over the forecast period of 2024 -2032.
North America is said to be the highest growing region due to the available resources, research funding.
Ans: Catalysts Fueling Growth in the mRNA Therapeutics Market are Innovations, Investments, and Expanded Applications.
The increase in demand for the MRNA based vaccines
The technological advancement in the field of mRNA therapeutic market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. mRNA Therapeutics Market Segmentation, by Application
7.1 Chapter Overview
7.2 Therapeutic
7.2.1 Therapeutic Market Trends Analysis (2020-2032)
7.2.2 Therapeutic Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Oncology
7.3.1 Oncology Market Trends Analysis (2020-2032)
7.3.2 Oncology Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Rare Genetic Diseases
7.4.1 Rare Genetic Diseases Market Trends Analysis (2020-2032)
7.4.2 Rare Genetic Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Respiratory Diseases
7.5.1 Respiratory Diseases Market Trends Analysis (2020-2032)
7.5.2 Respiratory Diseases Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Others
7.3.1 Others Market Trends Analysis (2020-2032)
7.3.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. mRNA Therapeutics Market Segmentation, by Type
8.1 Chapter Overview
8.2 Prophylactic
8.2.1 Prophylactic Market Trends Analysis (2020-2032)
8.2.2 Prophylactic Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Therapeutic
8.3.1 Therapeutic Market Trends Analysis (2020-2032)
8.3.2 Therapeutic Market Size Estimates and Forecasts to 2032 (USD Million)
9. mRNA Therapeutics Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals & Clinics
9.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
9.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Research Organizations
9.3.1 Research Organizations Market Trends Analysis (2020-2032)
9.3.2 Research Organizations Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.4 North America mRNA Therapeutics Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.5 North America mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.2 USA mRNA Therapeutics Market Estimates and Forecasts, by Type (2020-2032) (USD Million)
10.2.6.3 USA mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.7.2 Canada mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.2.7.3 Canada mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.8.2 Mexico mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.2.8.3 Mexico mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.4 Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.5 Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.6.2 Poland mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.6.3 Poland mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.7.2 Romania mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.7.3 Romania mRNA Therapeutics Market Estimates and Forecasts, by End Use(2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.2 Hungary mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.8.3 Hungary mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.9.2 Turkey mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.9.3 Turkey mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.4 Western Europe mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.5 Western Europe mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.6.2 Germany mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.6.3 Germany mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.7.2 France mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.7.3 France mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.8.2 UK mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.8.3 UK mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.9.2 Italy mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.9.3 Italy mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.10.2 Spain mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.10.3 Spain mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.11.2 Netherlands mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.11.3 Netherlands mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.12.2 Switzerland mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.12.3 Switzerland mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.13.2 Austria mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.13.3 Austria mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.4 Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.5 Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.6.2 China mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.6.3 China mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.7.2 India mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.7.3 India mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.8.2 Japan mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.8.3 Japan mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.9.2 South Korea mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.9.3 South Korea mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.10.2 Vietnam mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.10.3 Vietnam mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.11.2 Singapore mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.11.3 Singapore mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.12.2 Australia mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.12.3 Australia mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.4 Middle East mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.5 Middle East mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.6.2 UAE mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.6.3 UAE mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.7.2 Egypt mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.7.3 Egypt mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.9.2 Qatar mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.9.3 Qatar mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.4 Africa mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.2.5 Africa mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.2 South Africa mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.2.6.3 South Africa mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.7.2 Nigeria mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.2.7.3 Nigeria mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America mRNA Therapeutics Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.4 Latin America mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.6.5 Latin America mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.6.2 Brazil mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.6.6.3 Brazil mRNA Therapeutics Market Estimates and Forecasts, by End Use(2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.7.2 Argentina mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.6.7.3 Argentina mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.8.2 Colombia mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.6.8.3 Colombia mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America mRNA Therapeutics Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America mRNA Therapeutics Market Estimates and Forecasts, by Type(2020-2032) (USD Million)
10.6.9.3 Rest of Latin America mRNA Therapeutics Market Estimates and Forecasts, by End User(2020-2032) (USD Million)
11. Company Profiles
11.1 Moderna Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 BioNTech SE
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 CureVac N.V.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Arcturus Therapeutics
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Argos Therapeutics Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Sanofi
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 GSK Plc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Sangamo therapeutics
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 AstraZeneca
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Pfizer Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusio
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Application:
Rare genetic disease
Respiratory disease
Infectious disease
By Type:
Prophylactic vaccines
Therapeutic Vaccines
Therapeutic Drugs
By End User:
Hospitals and clinics
Research Organizations
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Hormone Replacement Therapy Market Size was valued at USD 18.36 billion in 2023 and is expected to reach USD 29.02 billion by 2032 and grow at a CAGR of 5.31% over the forecast period 2024-2032.
The Research Antibodies Market Size was valued at USD 1.4 billion in 2023 and expected to reach USD 2.3 billion by 2032 and grow at a CAGR of 5.5%.
The Antiviral Drugs Market size was estimated USD 69.92 billion in 2023 and is expected to reach USD 61.62 billion By 2031 at a CAGR of -1.79% during the forecast period of 2024-2031.
The Global Radiopharmaceuticals Market Size was USD 5.0 billion in 2023 & projected to grow at a CAGR of 10.4%, reaching USD 16.6 billion by 2032.
The Anti-Inflammatory Drugs Market Size was valued at USD 95.23 billion in 2023, and is expected to reach USD 177 billion by 2032, and grow at a CAGR of 7.13% over the forecast period 2024-2032.
The Fertility Services Market Size was valued at USD 40.89 Billion in 2023 and is expected to reach USD 99.60 Billion by 2032 and grow at a CAGR of 10.43% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
